DI-007

EFFICACY STUDY OF ABIRATERONE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) AFTER DOCETAXEL

Arias Moya MA, Castillo Bazán E, Bécares Martínez FJ, Tortajada Esteban EV, Bonilla Porras M, Hernández Segurado M .
University Hospital Fundación Jimenez Díaz , Department of Pharmacy , Madrid, Spain.

Purpose: To compare the characteristics, OS and PFS of patients who have received abiraterone in in metastatic castration-resistant prostate cancer (mCRPC) after docetaxel in our hospital with those of the phase 3 clinical study (CS)

Material and methods: Retrospective observational study, including all patients who have received abiraterone from marketing to April 2013. Data collected: ECOG, hematologic, hepatic, renal and heart function before treatment, time of progression with docetaxel, PFS and OS.

Results: We studied 6 patients:

- Time of progression with docetaxel was less than six months in all patients.
- 100% of patients had ECOG≤2.
- Hepatic function correct in all patients
- Only one had poor renal and hematologic function before treatment, with GFR = 39ml/min and hemoglobin <9.
- Heart function only was studied in four patients who had FEVI > 50%.

In April 2013, four patients had died and one patient had finished treatment after progression.

- The median OS was 1.9 months. (n=4)
- The median PFS was 2.9 months. (n=5)

Another patient was still in treatment since March 2012.
Five patients met the inclusion and exclusion criteria of CS (except serum testosterone levels that could not be verified due to the lack of analytical data). The patient, who did not meet exclusion criteria of CS, had brain metastasis, his OS and PFS was 20 days.





Conclusion:

- Although most of the patients met the inclusion criteria, OS and PFS results were much lower than those of the CS.
- Now, in our hospital there is a mCRPC protocol approved in February 2013 that contemplates the inclusion and exclusion criteria of CS and only patients who meet these criteria begin treatment.

CONFLICT OF INTEREST: No conflict of interest